First Clinical Use of the MiRus™ 3DR™ Printed Lumbar Interbody Fusion System

June 11, 2020

MiRus announced that it received FDA 510(k) clearance for its 3DR™ (Randomized) Printed Lumbar Interbody Fusion System which consists of the CALLISTO 3DR™ PLIF, HYPERION 3DR™ TLIF, CALYPSO 3DR™ LLIF and the ANTARES 3DR™ ALIF.

“The HYPERION 3DR TLIF is the first interbody with stiffness equivalent to cancellous bone, providing improved load sharing, reduced risk of subsidence and potentially superior fusion rates,” noted Alan McGee MD, Orthopaedic Surgeon at OrthoNortheast in Fort Wayne, Indiana.

MiRus currently leads the industry in innovative clinical solutions with the smallest pedicle screws, lowest profile cervical plate, and a real-time intra-operative sagittal alignment system. With the launch of the 3DR™ Interbody System, MiRus has set the benchmark for interbodies with a stiffness of 0.53 GPa, the lowest stiffness of any interbody in the world and in the same range as cancellous bone.

After using the new Hyperion TLIF interbody, James Mok, MD, MBA,  Orthopedic Spine Surgeon with Dupage Medical Group, Elmhurst, IL noted, “The interbody has the unique combination of a big graft window, which I consider important in order to allow bridging bone that can be evaluated on x-ray, combined with the benefits of 3D printing to mimic normal bone architecture and in-growth. My practice is almost exclusively MIS and in combination with the smallest profile pedicle screws from MiRus, I am excited to have these PLIF and TLIF interbodies available because of their handling characteristics and x-ray appearance.”

Faiz Ahmad MD, Associate Professor, Emory University Department of Neurosurgery, Atlanta observed, “The unique open structure modeled after the cancellous bone promotes bony on-growth and in-growth as well as providing the largest graft volume of any interbody on the market. I am also impressed with the low radio-density of the interbody allowing for easy postoperative visualization.”

Jay S. Yadav MD, Founder and CEO of MiRus, stated, “We have collaborated with an outstanding group of orthopaedic and neurosurgeons to develop transformative interbody solutions. With the shift in the market to 3D printed interbodies, the MiRus 3DR™ Printed Lumbar Interbody Fusion System designed with a randomized lattice structure that mimics the organic structure of bone, sets the benchmark for matching the stiffness and porosity of cancellous bone.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”